Silence Therapeutics plc (SLNCF)
OTCMKTS · Delayed Price · Currency is USD
6.52
0.00 (0.00%)
Nov 4, 2026, 4:00 PM EST
Silence Therapeutics Revenue
Silence Therapeutics had revenue of $624.83K in the twelve months ending June 30, 2026, down -97.63% year-over-year. In the year 2025, Silence Therapeutics had annual revenue of $568.83K, down -98.66%. That makes Silence Therapeutics the 44,299th largest company in the world by revenue and 6,271st in the United States.
Revenue (ttm)
624.83K
Revenue Growth
-97.63%
P/S Ratio
1,938.45
Revenue / Employee
6.99K
Employees
88
Market Cap
1.19B
Revenue by Geography
- UK 43.11M 99.7%
- Germany 144.00K 0.3%
Fiscal year ended Dec 31, 2024 See the full Silence Therapeutics breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 568.83K | -41.89M | -98.66% |
| Dec 31, 2024 | 42.45M | 10.81M | 34.17% |
| Dec 31, 2023 | 31.64M | 9.99M | 46.12% |
| Dec 31, 2022 | 21.66M | 4.87M | 29.01% |
| Dec 31, 2021 | 16.78M | 9.29M | 124.07% |
| Dec 31, 2020 | 7.49M | 7.17M | 2,215.11% |
| Dec 31, 2019 | 323.57K | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | 21.62K | -928.69K | -97.72% |
| Dec 31, 2016 | 950.31K | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | 23.37K | -170.40K | -87.94% |
| Dec 31, 2013 | 193.77K | -70.63K | -26.71% |
| Dec 31, 2012 | 264.40K | -812.57K | -75.45% |
| Dec 31, 2011 | 1.08M | -2.61M | -70.75% |
| Dec 31, 2010 | 3.68M | 893.28K | 32.03% |
| Dec 31, 2009 | 2.79M | -435.52K | -13.51% |
| Dec 31, 2008 | 3.22M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Vaxart | 243.07M |
| Sangamo Therapeutics | 34.56M |
| Nuo Therapeutics | 5.20M |
| Northwest Biotherapeutics | 2.17M |
| ZIVO Bioscience | 209.03K |
| Arch Biopartners | 113.25K |
Silence Therapeutics News
- 1 day ago - Silence Therapeutics Announces Oral Presentation on SANRECO Phase 2 Study of Divesiran in Polycythemia Vera at ASH 2026 - Business Wire
- 15 days ago - Silence Therapeutics downgraded to Neutral from Buy at H.C. Wainwright - TheFly
- 16 days ago - BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Silence Therapeutics plc (Nasdaq – SLN), Option Care Health, Inc. (Nasdaq – OPCH), RXO Inc. (NYSE – RXO), Sangoma Technologies Corporation (Nasdaq – SANG) - GlobeNewsWire
- 17 days ago - Silence Therapeutics downgraded to Hold from Buy at Jefferies - TheFly
- 17 days ago - Why Merck KGaA Is Paying a 130% Premium for This Gene-Silencing Tech - Barrons
- 17 days ago - Silence Therapeutics downgraded to Market Perform from Outperform at William Blair - TheFly
- 17 days ago - Why Is Silence Therapeutics (SLN) Stock Up 125% Today? - TipRanks
- 17 days ago - Silence Therapeutics downgraded to Neutral from Buy at Chardan - TheFly